Response to IQWiG assessment: Agendia’s Chief Clinical Officer affirms clinical utility of MammaPrint® in identifying breast cancer patients who can safely forego chemotherapy, following MINDACT trial

Gene expression-based tests are an integral part of modern oncology treatment strategies The MammaPrint® test, supported by the MINDACT study, reflects the leading edge technology and evidence for patients and physicians in need of clinically relevant information on which to … Continued